White Paper:
The Role of Digital Pathology in Accelerating the Drug Development Process

Digital pathology is transforming life science research and drug development. However, to achieve the potential benefits, organizations must identify and address key barriers and challenges in each phase of the research process.

  • Drug Discovery: The global growth of multinational organizations and CROs can create a siloed and fragmented approach to data management.
  • Preclinical Research: Standardization for grading slides in quality assurance and proficiency is a challenge—one that is amplified by geographically distributed research teams.
  • Clinical Trials: Trial data must accurately reflect the population being studied, but organizations may lack an efficient method for identifying subjects who meet the eligibility criteria. Screening the massive volume of data in EHRs, however, can be labor-intensive and slow.
  • Translational Medicine: Organizations who have embraced digital pathology may still face challenges with the usability of their technology—lack of flexibility in image management, repository sharing and collaboration, as well as storage capacity limitations.

This white paper provides an overview of the many challenges inherent within each of these phases, and explores how digital pathology can address these challenges to accelerate the speed and overall success of the drug development process.

About Proscia: Proscia’s mission is to transform cancer research and diagnosis with intelligent software that changes the way the world practices pathology, building tools that are redefining pathology and giving pathologists better ways to fight diseases such as cancer today.

Download the White Paper